-
Nanaomycin A: Targeting DNMT3B-Driven NEPC
2026-09-19
Therapy-resistant prostate cancer can evolve through epigenetic lineage plasticity. This thought-leadership article examines how DNMT3B supports neuroendocrine prostate cancer progression, how (S,S)-Nanaomycin A was used to pharmacologically interrogate that biology, and what translational researchers should consider when developing DNMT3B-focused studies.
-
CFDA SE Cell Tracer Kit: Practical Guide
2026-09-19
The CFDA SE Cell Tracer Kit provides persistent fluorescent labeling for cell proliferation studies, cell lineage tracing, and selected in vitro or in vivo tracking workflows. It is intended for durable covalent marking over several days, not reversible staining, rapid washout, or real-time applications that require dye replenishment.
-
Miltefosine Activates ERK in Leukopenia Research
2026-09-18
A study in Biochemical and Biophysical Research Communications identifies Miltefosine as a promoter of neutrophil differentiation through Ras/MEK/ERK signaling. Its integrated cell, irradiation-induced leukopenia, transcriptomic, docking, and inhibitor experiments provide a mechanistic framework for investigating hematopoietic recovery, while also highlighting the need for further validation beyond preclinical models.
-
BMS 599626 dihydrochloride Workflows
2026-09-18
Build reproducible EGFR/HER2 signaling, proliferation, and xenograft-oriented workflows with BMS 599626 dihydrochloride. The guide pairs nanomolar receptor pharmacology with AI-informed assay design while clearly separating validated evidence from exploratory senescence applications.
-
Oltipraz, Nrf2, and the Next MASLD Research Playbook
2026-09-17
Oltipraz offers a defined way to interrogate Nrf2-dependent phase II enzyme induction in MASLD research. By connecting chemoprevention biology with autophagy and ferroptosis readouts, translational teams can move beyond pathway activation toward mechanistically resolved liver-injury models.
-
Foretinib (GSK1363089) Assay Workflows
2026-09-17
Build more informative cancer assays with Foretinib by separating growth arrest from cell death and pairing viability data with motility, invasion, and metastasis-relevant readouts. This practical workflow uses concentration-aware design, orthogonal validation, and troubleshooting strategies for reproducible multikinase inhibitor studies.
-
Ganetespib (STA-9090) Workflow Guide
2026-09-16
Build reproducible Ganetespib assays around Hsp90 client-protein depletion, dose-response design, and orthogonal cell-death readouts. This guide translates the compound’s cancer-research value into practical lung cancer cell line studies while using a recent norovirus secretion study as a carefully bounded source of assay-design insight.
-
Bestatin Inhibition of Leucine Aminopeptidase
2026-09-15
The reference study used high-resolution X-ray crystallography to show how Bestatin occupies the active site of bovine lens leucine aminopeptidase and coordinates a catalytically relevant zinc ion. Its transition-state-like binding model connects inhibitor recognition with a proposed mechanism for peptide hydrolysis, providing a structural basis for interpreting aminopeptidase inhibition experiments.
-
HNRNPU K181 Lactylation Reprograms Cervical Cancer
2026-09-15
This Advanced Science study identifies HNRNPU K181 lactylation as a lactate-responsive mechanism that stabilizes HNRNPU, promotes PHGDH expression, and redirects serine metabolism in cervical cancer. Its integrated molecular, metabolic, and in vivo evidence provides a framework for testing how non-histone modification controls RNA processing and tumor growth.
-
Toremifene in Prostate Cancer Research
2026-09-14
Toremifene offers a practical SERM-based framework for testing hormone-responsive cancer biology alongside metastasis-associated calcium signaling. This workflow connects concentration-controlled cell growth assays with STIM1/TSPAN18 mechanistic readouts while clearly separating established evidence from testable research hypotheses.
-
EZ Cap™ Firefly Luciferase mRNA: Assay Design
2026-09-14
Discover how EZ Cap™ Firefly Luciferase mRNA can function as more than a reporter by separating delivery, endosomal release, and translation in RNA experiments. This guide combines molecular design, assay controls, handling parameters, and mechanistic insights from recent nanoparticle research.
-
How Drug Response Metrics Improve Cancer Assays
2026-09-13
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent components of anticancer drug response. The framework supports better time-resolved assay design, more cautious interpretation of viability data, and clearer translation between cytostatic and cytotoxic effects.
-
AmpliFold Capture-and-Release for Sensitive LFAs
2026-09-12
The reference study introduces AmpliFold, a capture-and-release strategy that addresses the fast-binding constraints of lateral flow assays by temporarily sequestering analyte complexes and enabling high-affinity rebinding. In a HER2 model, the approach improved detection performance by up to 16-fold and retained sensitivity gains with large gold nanoparticles and human-serum samples.
-
FPH1 (BRD-6125) Hepatocyte Workflow Guide
2026-09-12
FPH1 (BRD-6125) supports functional expansion of primary human hepatocytes while preserving decision-relevant readouts such as albumin, CYP3A4, and AFP. This practical guide connects controlled proliferation assays with iPS-derived hepatocyte workflows and explains how a light-regulated translation study can inform, but not replace, hepatocyte assay design.
-
SB-505124 Hydrochloride and Cell Mechanics
2026-09-11
A translational perspective on using SB-505124 hydrochloride to dissect ALK4/5/7 signaling, fibroblast activation, and the mechanobiology questions raised by the MRTFA-KCNMB1 axis in cancer.